Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 230

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 230
---
 Members with respect to the shares of ParentCo Common Stock that will be issued as consideration under the Business Combination Agreement. The Lock-Up Agreement includes, among other things, the following provisions:

Certain Liminatus Members will not be able to transfer any shares of ParentCo Common Stock beneficially owned or otherwise held by them for a period that is the earlier of: (a) for one-third of the shares, six months after the date of closing, for one-third of the shares, twelve months after the date of closing; and for one-third of the shares, twenty-four months after the date of closing; (b) the date on which the closing price of the ParentCo Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and similar transactions) for any 20 trading days within any 30-trading day period or (c) the date on which ParentCo completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of ParentCo’s stockholders having the right to exchange their shares of ParentCo common stock for cash, securities or other property.

The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Lock-Up Agreement, a copy of which is attached hereto as Annex G and is incorporated herein by reference.

On August 9, 2024, ParentCo and Sponsor entered into an amendment to the Lock-Up Agreement to grant a waiver of the lock-up restrictions contained in the Lock-Up Agreement with respect to an aggregate of 3.64 million ParentCo Shares to be held by certain Liminatus Members. The Lock-Up Agreement was subsequently amended on January 2, 2025 to grant a waiver of the lock-up restrictions contained in the Lock-Up Agreement with respect to an aggregate of 6.24 million ParentCo Shares. The business purpose for the waiver was to assist ParentCo in meeting the Nasdaq initial listing standards. No consideration was paid to ParentCo or the Sponsor in connection with such waiver.

#### Additional Agreements to be Executed at Closing
Registration Rights Agreement

In connection with the consummation of the Business Combination, ParentCo will enter into an Amended and Restated Registration Rights Agreement (the “RRA”) with Sponsor, Cantor, certain former members of Liminatus and the PIPE Investor. The RRA includes, among other things, the following provisions:

ParentCo will be